170,181 Johnson & Johnson $JNJ Shares Sold by Russell Investments Group Ltd.

Key Points

• Russell Investments reduced its Johnson & Johnson stake by 6.4%, selling 170,181 shares in the third quarter. It still held 2.51 million shares, worth about $664 million at quarter-end.
• J&J reported quarterly adjusted earnings of $2.59 per share, topping the $2.53 consensus, while revenue rose 5.9% year over year to $25.40 billion. The company declared a $1.34 quarterly dividend.
• Analysts’ consensus rating was “Moderate Buy,” with an average price target of $275.92. Two company executives also reported stock sales during the period.

Russell Investments Group Ltd. cut its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,505,319 shares of the company's stock after selling 170,181 shares during the period. Johnson & Johnson accounts for 0.6% of Russell Investments Group Ltd.'s portfolio, making the stock its 19th largest holding. Russell Investments Group Ltd. owned 0.10% of Johnson & Johnson worth $664,052,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $28,000. Navigoe LLC increased its holdings in shares of Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company's stock worth $38,000 after acquiring an additional 55 shares during the last quarter. Matrix Trust Co raised its stake in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after acquiring an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $43,000. Finally, Hanseatic Management Services Inc. acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $52,000. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on JNJ. UBS Group set a $270.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 14th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. Scotiabank restated an "outperform" rating and set a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Finally, Royal Bank Of Canada decreased their price target on shares of Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $275.92.

Insider Activity

In related news, EVP Jennifer Taubert sold 15,000 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $283.69 on Friday. The stock has a 50 day simple moving average of $266.83 and a 200 day simple moving average of $249.54. The stock has a market cap of $682.93 billion, a P/E ratio of 42.98, a PEG ratio of 2.77 and a beta of 0.22. Johnson & Johnson has a 1-year low of $193.45 and a 1-year high of $286.08. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company's revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson's dividend payout ratio is 81.21%.

Key Stories Impacting Johnson & Johnson

Investors following JNJ have been watching these stories:

• Positive Sentiment: J&J reported favorable Phase 3 results for CAPLYTA in adults with bipolar I disorder, with the drug providing rapid relief of manic symptoms. Positive data could strengthen the case for expanding the medicine’s use and future sales. Johnson & Johnson Reports Favorable Data For Bipolar Study
• Positive Sentiment: The company is backing Francis Medical as it advances its Vanquish water-vapor therapy device for prostate cancer through the FDA premarket approval process. J&J also led a $100 million funding round for Delix Therapeutics, supporting development of psychedelic-inspired depression treatments. The deals broaden its potential reach in cancer care and psychiatry, though both carry development and regulatory risk. J&J leads Francis Medical investment to fund prostate cancer device Johnson & Johnson backs new cancer device and leads $100 million depression bet
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares on Nov. 10 as part of a broader increase across all of the fund’s holdings. The purchase provides an institutional-demand datapoint but was not specific to J&J. State Street Health Care SPDR adds Johnson & Johnson

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.